Paul J. Brindley, Melinda Bachini, Sumera I. Ilyas, Shahid A. Khan, Alex Loukas, Alphonse E. Sirica, Bin Tean Teh, Sopit Wongkham, Gregory J. Gores

Research output: Contribution to journalReview articlepeer-review


Cholangiocarcinoma (CCA) is a highly lethal adenocarcinoma of the hepatobiliary system, which can be classified as intrahepatic, perihilar and distal. Each anatomic subtype has distinct genetic aberrations, clinical presentations and therapeutic approaches. In endemic regions, liver fluke infection is associated with CCA, owing to the oncogenic effect of the associated chronic biliary tract inflammation. In other regions, CCA can be associated with chronic biliary tract inflammation owing to choledocholithiasis, cholelithiasis, or primary sclerosing cholangitis, but most CCAs have no identifiable cause. Administration of the anthelmintic drug praziquantel decreases the risk of CCA from liver flukes, but reinfection is common and future vaccination strategies may be more effective. Some patients with CCA are eligible for potentially curative surgical options, such as resection or liver transplantation. Genetic studies have provided new insights into the pathogenesis of CCA, and two aberrations that drive the pathogenesis of non-fluke-associated intrahepatic CCA, fibroblast growth factor receptor 2 fusions and isocitrate dehydrogenase gain-of-function mutations, can be therapeutically targeted. CCA is a highly desmoplastic cancer and targeting the tumour immune microenvironment might be a promising therapeutic approach. CCA remains a highly lethal disease and further scientific and clinical insights are needed to improve patient outcomes.

Original languageEnglish (US)
Article number65
JournalNature Reviews Disease Primers
Issue number1
StatePublished - Dec 2021

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Cholangiocarcinoma'. Together they form a unique fingerprint.

Cite this